(Q34406737)

2 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

VEGF-targeted therapy in metastatic renal cell carcinoma (English)

1 reference

2 August 2017

Brian I Rini

1

1 reference

2 August 2017

1 March 2005

1 reference

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

3

1 reference

2 August 2017

191-197

1 reference

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

2 August 2017

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/20459

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NG0594-85

Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas.

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Vascular endothelial growth factor expression is increased in renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

The biology of vascular endothelial growth factor

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

30 December 2023

Genetics of human cancer

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Identification of the von Hippel-Lindau disease tumor suppressor gene

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Discovery of a novel Raf kinase inhibitor

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Molecularly targeted therapy in renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Tumor suppression and transcription elongation: the dire consequences of changing partners

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1634/THEONCOLOGIST.10-3-191

10.1634/THEONCOLOGIST.10-3-191

30 December 2023

Identifiers

DOI

1 reference

release_imfrwp4eavfoxobr6nifriftni

2 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/imfrwp4eavfoxobr6nifriftni

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15793222

1 reference

PubMed ID

15793222